Hui Kai Koh, MBBS; Stephanie Fook-Chong; Haur Yueh Lee, MBBS, MRCP (UK), MMed (Int Med)
JAMA Dermatol. 2020;156(12):1294-1299. doi:10.1001/jamadermatol.2020.3654
This cohort study assesses the performance of ABCD-10 compared with SCORTEN for patients with epidermal necrolysis in Singapore.
Selin Tokez, MSc; Loes Hollestein, PhD; Marieke Louwman, PhD; et al.
has audio
JAMA Dermatol. 2020;156(12):1300-1306. doi:10.1001/jamadermatol.2020.3677
This cohort study calculates annual age-standardized incidence rates for histopathologically confirmed first and multiple cutaneous squamous cell carcinoma per patient and estimates future cutaneous squamous cell carcinoma incidence rates up to 2027.
-
Audio Author Interview:
Multiple vs First Incidence of Cutaneous Squamous Cell Carcinoma and Estimation of Future Incidences
Michael R. Sargen, MD; Elizabeth K. Cahoon, PhD; Charles F. Lynch, MD, PhD; et al.
JAMA Dermatol. 2020;156(12):1307-1314. doi:10.1001/jamadermatol.2020.3111
This cohort study uses registry-based data of US organ transplant recipients to assess the incidence of sebaceous carcinoma and patient survival among solid organ transplant recipients from 1987 through 2017.
Lawrence F. Eichenfield, MD; Wendy McFalda, MD; Bradford Brabec, MD; et al.
open access
has active quiz
JAMA Dermatol. 2020;156(12):1315-1323. doi:10.1001/jamadermatol.2020.3238
These randomized clinical trials examine the efficacy and safety of VP-102, a drug-device combination containing cantharidin, 0.7% (w/v), in treatment of patients with molluscum contagiosum.
Magdalena Claeson, MD, PhD; Nirmala Pandeya, MMedSc, PhD; Jean-Claude Dusingize, MD, PhD; et al.
JAMA Dermatol. 2020;156(12):1324-1332. doi:10.1001/jamadermatol.2020.4097
This cohort study uses data from the QSkin Sun and Health study to assess the incidence rate and risk factors for keratoacanthoma among residents of Queensland, Australia.
Kristian Reich, MD; Kenji Kabashima, MD; Ketty Peris, MD; et al.
open access
JAMA Dermatol. 2020;156(12):1333-1343. doi:10.1001/jamadermatol.2020.3260
This randomized clinical trial assesses the efficacy and safety of 4 mg and 2 mg of baricitinib in combination with background topical corticosteroid therapy in adults with moderate to severe AD who previously had an inadequate response to topical corticosteroid therapy.
Matthias Augustin, MD; Jo Lambert, MD, PhD; Carla Zema, PhD; et al.
open access
JAMA Dermatol. 2020;156(12):1344-1353. doi:10.1001/jamadermatol.2020.3617
This secondary analysis of 2 randomized clinical trials compares patient-reported outcomes of treatment with risankizumab vs ustekinumab and placebo in psoriasis symptoms, health-related quality of life, and mental health among patients with moderate to severe psoriasis.